VectraCor

VectraCor has patented technology to non-invasively detect heart attacks within seconds and derive a 22 lead ECG.

  • Stage $500K in TTM Revenue
  • Industry Medical Devices and Equipment
  • Location United States
  • Currency USD
  • Founded March 2009
  • Employees 7
  • Website vectracor.com

Company Summary

VectraCor has disruptive patented technology for the #1 killer in the world, Cardiovascular Disease. Our FDA approved and CE Mark product is the only monitor/ECG machine with a Cardiac Electrical Biomarker-CEB™ for the real-time detection of ECG changes suggestive of an AMI plus the capability to derive a 15-22 lead ECG, non-invasively using only 5 electrodes. This could result in faster intervention to save heart muscle and potential lives.

Team

  • Thomas Stairs, MD
    MAB

    Harvard Group

  • Brad Schreck
    Pres. & CEO

  • Dr. David Schreck
    Chief Medical Officer

  • Frank Peacock, MD
    MAB

    Baylor College of Medicine

  • Terry Bauch, MD
    MAB

    Geisinger Wyoming Valley Medical Center

  • William Dalsey, MD
    MAB

    Chair of the Department of Emergency Medicine
    Capital Health Systems

  • Brad Schreck

Advisors

  • Paul Peter Nicolai
    Lawyer
    Unconfirmed
    Glenn Yannotta
    Accountant
    Unconfirmed

Previous Investors

  • David Leishman|Dr. William Richardson|Niles Noblitt & Carmen Cacciavillani
    Unconfirmed
    James Pinkin, Dr. Roscoe Moore, Dr. Robert fishberg
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free